Piper Sandler Cuts Humana (NYSE:HUM) Price Target to $272.00

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Humana (NYSE:HUM - Get Free Report) had its price target lowered by equities research analysts at Piper Sandler from $288.00 to $272.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a "neutral" rating on the insurance provider's stock. Piper Sandler's price objective indicates a potential upside of 6.57% from the stock's previous close.

Several other research firms also recently commented on HUM. Robert W. Baird decreased their price target on shares of Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a research note on Friday, July 25th. Oppenheimer upped their price objective on shares of Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a research report on Thursday, May 1st. Raymond James Financial raised shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective for the company in a research report on Thursday, May 1st. Mizuho upped their price objective on shares of Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 9th. Finally, Barclays set a $275.00 target price on shares of Humana in a report on Thursday. Sixteen equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $282.00.

Humana Stock Down 2.4%

HUM stock traded down $6.23 during mid-day trading on Thursday, hitting $255.24. 477,442 shares of the company were exchanged, compared to its average volume of 1,730,917. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.91 and a current ratio of 1.91. The firm has a market cap of $30.80 billion, a P/E ratio of 18.01, a P/E/G ratio of 1.59 and a beta of 0.44. The firm's 50 day simple moving average is $234.17 and its 200 day simple moving average is $255.74. Humana has a 1-year low of $206.87 and a 1-year high of $382.72.

Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The firm had revenue of $32.39 billion for the quarter, compared to analyst estimates of $31.85 billion. Humana had a return on equity of 14.47% and a net margin of 1.42%. Humana's quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $6.96 earnings per share. On average, sell-side analysts predict that Humana will post 16.47 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Revolve Wealth Partners LLC purchased a new position in shares of Humana during the fourth quarter worth about $202,000. American Century Companies Inc. boosted its stake in Humana by 8.8% in the fourth quarter. American Century Companies Inc. now owns 12,655 shares of the insurance provider's stock worth $3,211,000 after buying an additional 1,027 shares in the last quarter. Orion Portfolio Solutions LLC boosted its stake in Humana by 3.7% in the fourth quarter. Orion Portfolio Solutions LLC now owns 4,834 shares of the insurance provider's stock worth $1,226,000 after buying an additional 171 shares in the last quarter. Summit Financial LLC boosted its stake in Humana by 19.2% in the fourth quarter. Summit Financial LLC now owns 1,409 shares of the insurance provider's stock worth $359,000 after buying an additional 227 shares in the last quarter. Finally, HighPoint Advisor Group LLC boosted its stake in Humana by 6.1% in the fourth quarter. HighPoint Advisor Group LLC now owns 1,509 shares of the insurance provider's stock worth $388,000 after buying an additional 87 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company's stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.